Keep this story going! Share below!
No.0, Compound Reserpine and Triamterene Tablets, is a new product innovation produced by China Resources Double-Crane Pharmaceutical Co., LTD. It developed to become one of the most successful and cost-efficient hypertensive drugs on the market. It fulfills goal 3 and goal 10, “good health and well being” and “Reduce Inequality” as it has potentially saved millions of lives from hypertension.
A research team led by Prof. Hua Luogeng, one of the most influential mathematicians and researchers in contemporary China, aimed to develop that very drug. No. 0 combines the philosophy of Traditional Chinese medicine, the pharmacological effects of Western medicine, and Hua Luogeng’s mathematical excellence and optimization method. After commencing production of No.0, and undergoing clinical observation in several major hospitals, word of its remarkable efficacy quickly spread. The State Health Ministry and drug administration later approved the production of Double-Crane Pharmaceutical. The state provides financial support. With the support of the state, it is very affordable and affordable for everyone who needs it. This is consistent with the sustainable goal 10 of reducing inequality.
The “zero” means a new beginning, Chinese original. These drugs were developed years ago and had definite antihypertensive effects, but the old drugs have many adverse reactions at the same time. Compound Reserpine Triamterene tablets are changed to four ingredients: hydrothiazide, trimethopterine, dihydrazidine sulfate, and reserpine. One component, functioning sedation, hypnosis, and anti-anxiety, was deleted, from the local level to the national standard during the upgrade process. To this very day, the No. 0 antihypertensive drug is still under mass production and distribution. It remains one of the most influential and cost-friendly hypertensive drugs on the market, meeting Goal 3: Good Health and Well-being of the 17 UN Sustainable Development Goals.
Additionally, the Double Crane sales team, responsible for sales of No.0, designed a “920 action plan” tailored to No.0. The plan includes starting from patients, promoting popular science activities in the community, comprehensively enhancing consumers’ knowledge and awareness of hypertension prevention to understand No.0 product simultaneously, and more importantly, paying attention to a healthy lifestyle. (Goal 3,10)
According to the interview, before the release of the No. 0 Antihypertensive, facing the traditional treatment process and effects of low-efficiency hypertension drugs, patients who were prescribed are required to take them three times a day, often 3-4 different tablets every time. A few people can insist and completely follow this medical recommendation; thus, the results of this treatment did not optimize people’s health. The unmanageable blood pressure diseases have increased demand for a more functional, convenient, and safer hypertensive drug.
After the country’s economic and trade development and changes, they began to seek more expensive imported drugs for treatment. Given the low level of national health and life safety, the treatment of hypertension must be highly concerned. At the same time, the problems of treatment support and drug consumption levels for hypertensive patients also urgently need to be resolved. Under the dual challenges of people’s health threats and the national economy, Prof. Hua Luogeng and Academician Hong Zhao Guang were concerned that the Chinese people could not effectively relieve high blood pressure under traditional medical treatment in the 1970s. So it began to devote itself to innovation, research, and development of a brand-new hypertension drug to improve health. Yi Tan stated, “The No.0 product has had a national mission since it was innovated”. The obligation towards the nation was absolutely a vital incentive to develop a new No.0. Double Crane was devoted to reinvigorating the national economy.
Double Crane decided to innovate and devote itself to the massive production of hypertension drugs to improve the health of the people and the import demand of national medications.
Because medicine involves human life, safety, and health, its impact must pass the test of practice and time. When Product 0 came out and began to be widely used because of its efficacy, the short-term effect it brought could be regarded as a great innovation in the Chinese medical field because it was the first antihypertensive drug in China. With completely independent intellectual property rights, it will become good news for hypertension patients. Think of it more in terms of long-term effects and impact.
No. 0 product plays an important role in the social environment and national drug funding as well as scientific research programs in the long term. To be specific, in addition to the commercial benefits brought by the massive No. 0 product consumption, it also promotes the efficiency and credibility of the country's local drug research and development. People will have a strong sense of trust in local medicines in the process of buying medicines, instead of blindly pursuing imported products. Of course, under the research and development of Double Crane Pharmaceutical, the health level of the people and the effect of hypertension treatment have been significantly improved.
Quantitatively speaking, aside from the fact that it is the most popular antihypertensive drug prescribed to patients with hypertension, the No. 0 has a 96.9% rate for significant symptom-reduction, and a 92.3% success rate at lowering blood pressure for patients with hypertension. A 5-year study also found that chances of stroke from patients with hypertension has seen a reduction of 89% and the death rate of stroke has decreased by over 76%. Chances of acute myocardial infarction have seen a reduction of 62% as well, making it one of the most successful medical developments in the 1970s in China. In addition, as a national economic entity, Double Crane's research and development of No. 0 products has provided effective assistance to the country's economic development. It assumes the social responsibility of an enterprise and provides an effective guarantee for the long-term healthy lives of the people.
After the IPO, Double Crane's main business revenue, net profit, and total profit increased by 47.6%, 20.8%, and 26.3% on average in three years respectively. The most basic business benefit of the No. 0 product is to help save medical costs for the people and obtain a large number of patients with relatively affordable hypertension treatment drugs. The advantage lies in attracting the vast consumer masses with reasonable prices and excellent effects accepted by the public. The promotion and successful sales of this product have drawn people's attention to the pharmaceutical strength of Double Crane Pharmaceutical. As a result, other types of drugs produced by the same pharmaceutical factory have also received widespread public attention. It is worth noting that the promotion and therapeutic effects of No. 0 products have provided Double Crane Pharmaceutical with a huge brand effect and commercial reputation, thereby generating more trust in the purchasing tendency of similar drugs. At the same time of gains profit, improving brand awareness. There is no doubt that the No. 0 product has brought substantial commercial benefits to Double Crane Pharmaceutical, thus providing basic financial support for other drug research and development of Double Crane Pharmaceutical.
Yi Tan mentioned, “because of the huge profits and achievements brought by Product 0, the company can expand and increase the sales of subsequent new products based on the original sales channel of product 0.” At the same time, the company's bountiful profits have led to better benefits for workers and higher wages, which Mrs. Tan says have increased by 30% in the last three years. Additionally, the success of No.0 allows the company to expand various new digital markets, for example, at Alibaba and Jingdong online pharmacies.
Its medicinal effects benefit the public. According to the clinical observation of 1,036 patients in Fuwai Hospital of Chinese Academy of Medical Sciences and Beijing Chaoyang Hospital, the symptom effective rate and effective hypotensive rate of tablets were 96.9% and 92.3%, respectively. “It has no adverse effect on liver, kidney, and platelets. It can antagonize reflex tachycardia. No significant increase in the incidence of gastrointestinal bleeding was observed” Yi Tan introduced. It is contributing to Goal 3 (Good Health).
Its fair price lets everyone afford it. Yi Tan said It is a much cheaper alternative when compared to traditional antihypertensive drugs. The study showed that the average cost-effectiveness of medicine No.0 was 418.1 yuan, whereas the average cost-effectiveness of traditional hypertensive drugs was 1057.7 yuan. Choosing No.0 could be very helpful to families who need the medication but cannot pay such high prices for the traditional medicines—contributing to Goal 10 (Reducing inequality in the society).
Another societal benefit of medicine No.0 is that the promotion of the medicine helps educate the public about many things involving hypertension and prevention. Yi Tan said, “at the same time No. 0 drugs promotion, we also provided patient education, free diagnosis service, free blood glucose measurement and other charitable activities for patients taking drugs at the grassroots level. We also invite experts to give lectures and provide continuing education and learning opportunities for primary doctors.” Comprehensively enhance consumers’ knowledge of hypertension prevention. This illustrates their contribution to Goal 3 (Good Health).
Aside from its direct benefit to society, the No. 0 has also provided numerous job opportunities domestically, reducing inequality. With nine factories and around 30,000 workers, No. 0 has provided a significant quantity of jobs while also improving their workers’ welfare. With the No. 0 reaching more patients with hyperintensity, the company has greatly increased worker wages and welfare so that the drug benefits the patients and the workers who put great efforts into its production. Following Goal 10.
Yi Tan, Sales Manager
In the face of profound changes in the internal and external environment of the enterprise, China Resources has actively adapted to the new economy and implemented the concept of "innovation, coordination, green, openness, and sharing". The company's economic strength, competitive vitality, and sustainable development ability, ranking at the forefront of domestic pharmaceutical companies. The company has won many honors such as "Top100 Chinese chemical and pharmaceutical enterprises", "green factory".